森萱医药
(830946)
| 流通市值：48.65亿 | | | 总市值：48.67亿 |
| 流通股本：4.27亿 | | | 总股本：4.27亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 260,780,605.31 | 125,565,724.8 | 537,136,066.43 | 388,292,807.26 |
| 营业收入 | 260,780,605.31 | 125,565,724.8 | 537,136,066.43 | 388,292,807.26 |
| 二、营业总成本 | 177,772,448.45 | 89,563,161.4 | 384,117,079.97 | 280,612,605.13 |
| 营业成本 | 134,210,670.19 | 68,147,644.73 | 303,074,084.84 | 219,229,158.2 |
| 税金及附加 | 4,176,589.47 | 1,910,951.11 | 6,998,284.82 | 4,986,962.87 |
| 销售费用 | 7,289,042.53 | 3,753,124.26 | 14,481,608.19 | 11,348,175.29 |
| 管理费用 | 25,665,750.45 | 13,740,994.41 | 57,542,288 | 41,365,002.22 |
| 研发费用 | 12,297,427.89 | 4,548,782.88 | 28,636,950.09 | 22,856,171.16 |
| 财务费用 | -5,867,032.08 | -2,538,335.99 | -26,616,135.97 | -19,172,864.61 |
| 其中:利息费用 | 40,920.96 | 11,797.95 | 583,687.08 | 535,558.76 |
| 其中:利息收入 | 6,382,420.47 | 2,654,133.72 | 25,244,158.81 | 20,303,787.34 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 854,982.69 | 484,059.14 | 1,464,962.91 | 1,386,469.86 |
| 加:投资收益 | 420,272.41 | 48,647.26 | 1,198,523.11 | 957,391.69 |
| 资产处置收益 | 4,478.7 | - | -190,269.32 | - |
| 资产减值损失(新) | -4,368,596.75 | -2,424,771.3 | -8,250,382.13 | -228,657.89 |
| 信用减值损失(新) | 981,538 | 638,867.84 | -2,369,004.11 | -613,608.27 |
| 其他收益 | 1,090,969.98 | 780,324.46 | 4,978,251.4 | 2,824,326.02 |
| 四、营业利润 | 81,991,801.89 | 35,529,690.8 | 149,851,068.32 | 112,006,123.54 |
| 加:营业外收入 | 0.16 | - | 1,600,678.96 | 7,002.39 |
| 减:营业外支出 | 5,640.5 | - | 4,240,098.05 | 3,433,430.92 |
| 五、利润总额 | 81,986,161.55 | 35,529,690.8 | 147,211,649.23 | 108,579,695.01 |
| 减:所得税费用 | 11,947,895.44 | 5,307,652.93 | 21,553,561.59 | 14,954,789.36 |
| 六、净利润 | 70,038,266.11 | 30,222,037.87 | 125,658,087.64 | 93,624,905.65 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 70,038,266.11 | 30,222,037.87 | 125,658,087.64 | 93,624,905.65 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 67,920,072.39 | 29,032,478.96 | 123,759,884.41 | 91,366,685.53 |
| 少数股东损益 | 2,118,193.72 | 1,189,558.91 | 1,898,203.23 | 2,258,220.12 |
| 扣除非经常损益后的净利润 | 66,192,565.89 | 28,283,639.73 | 116,722,626.76 | 87,439,366.88 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.16 | 0.07 | 0.29 | 0.21 |
| (二)稀释每股收益 | 0.16 | 0.07 | 0.29 | 0.21 |
| 九、综合收益总额 | 70,038,266.11 | 30,222,037.87 | 125,658,087.64 | 93,624,905.65 |
| 归属于母公司股东的综合收益总额 | 67,920,072.39 | 29,032,478.96 | 123,759,884.41 | 91,366,685.53 |
| 归属于少数股东的综合收益总额 | 2,118,193.72 | 1,189,558.91 | 1,898,203.23 | 2,258,220.12 |
| 公告日期 | 2025-08-29 | 2025-04-29 | 2025-04-14 | 2024-10-29 |
| 审计意见(境内) | | | 标准无保留意见 | |